Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

NCT ID: NCT00645177

Last Updated: 2013-01-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-07-31
• Study Completion Date: 2009-12-31

Brief Summary

The purpose of this study is to determine the effect of ABT-869 plus paclitaxel compared to paclitaxel alone on disease progression in metastatic breast cancer.

Detailed Description

Only the open-label lead-in portion of the study was enrolled (n=10). The randomized portion was not initiated. N = approximately 102 (90 randomized in a 1:1 ratio in Phase 2, approximately 6-12 enrolled in open-label lead-in to assess the tolerability of the combination) Phase 2, randomized, placebo-controlled, double-blind, multi-center study of the efficacy and tolerability of the ABT-869 + paclitaxel versus placebo for ABT-869 + paclitaxel in subjects with documented metastatic breast cancer in the first line metastatic therapy setting. An initial open-label, lead-in cohort of six subjects will be monitored for 2 cycles (8 weeks) to assess the PK interactions and the safety of the combination of 0.20 mg/kg QD ABT-869 and paclitaxel (90 mg/m2). Enrollment into the randomized portion will begin after a cohort has completed two cycles (8 weeks) of therapy and no toxicities prohibit the cohort from continuing on to Cycle 3. Alternative doses may be explored based on the tolerability of the combination.

Conditions

Metastatic Breast Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

A

In study, this arm is a randomized (blinded) to ABT-869 arm plus paclitaxel.

Note: Prior to randomization, approximately 6-12 subjects will be enrolled in open-label lead-in to assess the tolerability of the combination. The initial open-label, lead-in cohort of six subjects will be monitored for 2 cycles (8 weeks) to assess the PK interactions and the safety of the combination of 0.20 mg/kg QD ABT-869 and paclitaxel (90 mg/m2). Enrollment into the randomized portion will begin after a cohort has completed two cycles (8 weeks) of therapy and no toxicities prohibit the cohort from continuing on to Cycle 3.

Alternative doses may be explored based on the tolerability of the combination

Group Type: ACTIVE_COMPARATOR

ABT-869

Intervention Type: DRUG

0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle

paclitaxel

Intervention Type: DRUG

90 mg/m2 IV infusion over 1 hour, weekly every 3 out of 4 weeks

B

In study, this arm is a randomized (blinded) to placebo for ABT-869 plus paclitaxel arm.

Note: Prior to randomization, approximately 6-12 subjects will be enrolled in open-label lead-in to assess the tolerability of the combination. The initial open-label, lead-in cohort of six subjects will be monitored for 2 cycles (8 weeks) to assess the PK interactions and the safety of the combination of 0.20 mg/kg QD ABT-869 and paclitaxel (90 mg/m2). Enrollment into the randomized portion will begin after a cohort has completed two cycles (8 weeks) of therapy and no toxicities prohibit the cohort from continuing on to Cycle 3.

Alternative doses may be explored based on the tolerability of the combination

Group Type: PLACEBO_COMPARATOR

paclitaxel

Intervention Type: DRUG

90 mg/m2 IV infusion over 1 hour, weekly every 3 out of 4 weeks

Placebo for ABT-869

Intervention Type: DRUG

0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle

Interventions

ABT-869

0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle

Intervention Type: DRUG

paclitaxel

90 mg/m2 IV infusion over 1 hour, weekly every 3 out of 4 weeks

Intervention Type: DRUG

Placebo for ABT-869

0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subject must be female and > 18 years of age.
• Subject must be diagnosed with adenocarcinoma of the breast.
• Subject must have metastatic disease or locally recurrent disease that is not amenable to surgical resection with curative intent.
• No prior chemotherapy for locally recurrent or metastatic breast cancer.
• At least 12 months since prior adjuvant or neoadjuvant chemotherapy (including prior taxane therapy and prior anti-angiogenic therapy [i.e. bevacizumab or a TKI]).
• No HER-2 -over-expression (3+) breast cancer (unless treated with trastuzumab or lapatinib).
• Subject has measurable disease by RECIST criteria (randomized portion only).
• Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1.
• Subject must have adequate bone marrow, renal and hepatic function.
• Subject must have PTT < 1.5 x ULN and INR < 1.5.

Exclusion Criteria

• Subject has received anti-cancer therapy (other than chemotherapy) including investigational agents, or biologic therapy within 21 days or within a period defined by 5 half lives, whichever is shorter, prior to Study Day 1.
• Subject has not recovered to less than or equal to grade 1 clinically significant adverse effects/toxicities of the previous therapy.
• Subject has received radiation therapy within 14 days of Study Day 1.
• Subject has received anti-cancer hormonal therapy within 14 days of Study Day 1.
• Subject has undergone major surgery within 21 days of Study Day 1.
• The subject has untreated brain or meningeal metastases.
• Subject is receiving therapeutic anticoagulation therapy.
• Subject has a history of or currently exhibits clinically significant cancer related events of bleeding (e.g., hemoptysis).
• Subject currently exhibits symptomatic or persistent, uncontrolled hypertension.
• Subject has a history of myocardial infarction, stroke, or transient ischemic attack (TIA) within 6 months of study day 1.
• Subject has a documented left ventricular (LV) ejection fraction < 50%
• Subject has known autoimmune disease with renal involvement.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Genentech, Inc.

INDUSTRY

Sponsor Role: collaborator

AbbVie (prior sponsor, Abbott)

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Justin L. Ricker, MD

Role: STUDY_DIRECTOR

AbbVie

Locations

Site Reference ID/Investigator# 8352

San Francisco, California, United States

Site Reference ID/Investigator# 6920

Harvey, Illinois, United States

Site Reference ID/Investigator# 10181

Durango, DGO., , Mexico

Countries

United States; Mexico

Other Identifiers

2007-005905-23

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

M10-265

Identifier Type: -

Identifier Source: org_study_id